Literature DB >> 12390950

Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease.

Tilman Drüeke1, Véronique Witko-Sarsat, Ziad Massy, Béatrice Descamps-Latscha, Alain P Guerin, Sylvain J Marchais, Valérie Gausson, Gérard M London.   

Abstract

BACKGROUND: Increased common carotid artery intima-media thickness (CCA-IMT) is a marker of early atherosclerosis. Low-grade inflammation is associated with the pathogenesis of atherosclerosis. Low-grade inflammation and increased CCA-IMT are observed in end-stage renal disease (ESRD). Oxidative stress is involved in uremia-related inflammation. Advanced oxidation protein products (AOPP) are markers of oxidant-mediated protein damage in ESRD. Intravenous iron given to patients on hemodialysis (HD) might induce oxidative stress. We investigated the relationships between AOPP, iron therapy, and CCA-IMT in stable HD patients. METHODS AND
RESULTS: Plasma AOPP and blood chemistry, including iron status, were analyzed in a cohort of 79 ESRD patients on HD. Measurements of CCA-IMT and CCA diameter, as assessed by B-mode ultrasonography, were obtained in 60 patients. AOPP levels were elevated in ESRD patients, and in univariate (r=0.42, P<0.0001) and multivariate analyses (r=0.38, P<0.001), they correlated with serum ferritin and with the intravenous iron dose received during the 12 months preceding the study (ferritin, P<0001; AOPP, P<0.01). Univariate and multivariate analyses identified the AOPP concentration as being significantly associated with CCA-IMT (P=0.0197) and CCA wall-to-lumen ratio (r=0.560, P<0.0001). Independently of AOPP concentration, cumulative iron dose was positively related to CCA-IMT (P=0.015) in patients <60 years.
CONCLUSION: In ESRD patients, CCA-IMT and CCA wall-to-lumen ratio were associated with plasma AOPP, serum ferritin, and the annual intravenous iron dose administered. These findings support the concept of a role of oxidative stress in the early atherosclerosis of ESRD patients, which may be increased by the usually recommended doses of intravenous iron.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390950     DOI: 10.1161/01.cir.0000035250.66458.67

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  73 in total

Review 1.  The bone-vascular axis in chronic kidney disease.

Authors:  Linda Demer; Yin Tintut
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-07       Impact factor: 2.894

2.  Is Intravenous Iron Supplementation Safe to Administer to Patients on Hemodialysis with Active Infection--What Do We Know, and What More Do We Need to Know?

Authors:  Charles Lee Bennett; Terhi Hermanson
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-28       Impact factor: 8.237

3.  The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients.

Authors:  Mana Yahiro; Takahiro Kuragano; Aritoshi Kida; Rie Kitamura; Minoru Furuta; Yukiko Hasuike; Yoshinaga Otaki; Hiroshi Nonoguchi; Takeshi Nakanishi
Journal:  Clin Exp Nephrol       Date:  2012-01-24       Impact factor: 2.801

4.  Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease.

Authors:  Paolo Ferrari; Hemant Kulkarni; Shyam Dheda; Susanne Betti; Colin Harrison; Timothy G St Pierre; John K Olynyk
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

5.  Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease.

Authors:  Johannes Holle; Uwe Querfeld; Marietta Kirchner; Alexandros Anninos; Jürgen Okun; Daniela Thurn-Valsassina; Aysun Bayazit; Ana Niemirska; Nur Canpolat; Ipek Kaplan Bulut; Ali Duzova; Ali Anarat; Rukshana Shroff; Yelda Bilginer; Salim Caliskan; Cengiz Candan; Jerome Harambat; Zeynep Birsin Özcakar; Oguz Soylemezoglu; Sibylle Tschumi; Sandra Habbig; Ebru Yilmaz; Ayse Balat; Aleksandra Zurowska; Nilgun Cakar; Birgitta Kranz; Pelin Ertan; Anette Melk; Karolis Azukaitis; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2019-08-19       Impact factor: 3.714

6.  Assessment of oxidative, inflammatory, and fibrinolytic biomarkers and DNA strand breakage in hypercholesterolemia.

Authors:  Renata da Silva Pereira; Etiane Tatsch; Guilherme Vargas Bochi; Helena Kober; Thiago Duarte; Greice Franciele Feyh dos Santos Montagner; José Edson Paz da Silva; Marta Maria Medeiros Frescura Duarte; Ivana Beatrice Mânica da Cruz; Rafael Noal Moresco
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

7.  Cumulative iron dose and resistance to erythropoietin.

Authors:  A Rosati; C Tetta; J I Merello; I Palomares; R Perez-Garcia; F Maduell; B Canaud; P Aljama Garcia
Journal:  J Nephrol       Date:  2014-08-05       Impact factor: 3.902

8.  A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.

Authors:  Johann C B Nicholas
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.

Authors:  Hassan N Ibrahim; Robert N Foley; Rui Zhang; David T Gilbertson; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

10.  The association of biomarkers of iron status with peripheral arterial disease in US adults.

Authors:  Andy Menke; José Manuel Fernández-Real; Paul Muntner; Eliseo Guallar
Journal:  BMC Cardiovasc Disord       Date:  2009-08-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.